- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07719192
Effects of Alternate Nostril Breathing and Bellows Breath in COPD Patients
July 17, 2026 updated by: Riphah International University
Effects of Alternate Nostril Breathing and Bellows Breath on Sputum Clearance, Pulmonary Function Test and Quality of Life Among COPD Patients
COPD is a common respiratory disease characterized by progressive airflow obstruction, dyspnea, chronic cough, and sputum production.
Alternate nostril breathing and bellows breath are pranayama-based breathing techniques that may improve respiratory function and overall well-being.
This randomized clinical trial aims to compare the effects of these techniques on sputum clearance, pulmonary function tests, and quality of life in COPD patients.
The study will be conducted at Punjab Institute of Cardiology using convenient sampling.
Participants will be divided into two groups: Group A will perform alternate nostril breathing, while Group B will perform bellows breath exercises for 15-20 minutes daily over 3-4 weeks.
Outcome measures include sputum clearance, spirometry, and quality of life questionnaires.
Data will be analyzed using SPSS with significance set at p < 0.05.
The study may support the use of cost-effective, noninvasive breathing techniques for improving pulmonary function and quality of life in COPD patients.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
The respiratory ailment known as chronic obstructive pulmonary disease (COPD) is becoming more and more common all over the world.
It is characterized by a partiallyvolatile airway blockage.
It is characterized by growing and ongoing dyspnea, persistent coughing and sputum production.
Chronic cough and sputumare separaterisk factors for early death from COPD, and they are often closely associated withexacerbation.
Alternate nostril breathing and bellows breath are two commontechnique which is based on pranyama,which is yogic practice of breath control.
These techniques is utilize specific breathing pattern to in fluence the nervous system,energy flow and overall well being.
The objective of this study is to findtheeffect of alternate nostril breathing and bellows breath on sputumclearance,pulmonary function test and quality of life among COPD patients.
The study design will be randomized clinical trial.
It will conducted at Punjab instituteof cardiology.sample
size will be conducted through non-probability convenient sampling as per inclusion criteria participants will be randomly added intotwogroups. .
Group A[alternate nostril breathing] and Group B[bellows breath].
bothintervention will be performed for 15 to 20 min/day for 3 to 4 weeks.
Pre andpost intervention data will be collected.
Outcome measures include sputumclearance,spiromter and health related quality of life questionnaire.
Data will beanalyzed by using SPSS.
Paired or Independent t-test will be used to comparevariables between the two groups and within the two groups, with significance set at p< 0.05.
This study will provide evidence for the integration of noninvasive, cost effective strategies for the enhancement of PFT's and functional capacity and qualityof life.
Study Type
Interventional
Enrollment (Estimated)
54
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Muhammad Iqbal Tariq Phd*, Phd*
- Phone Number: 333826752
- Email: iqbal.tariq@riphah.edu.pk
Study Contact Backup
- Name: Nimra noor Noor, MS
- Phone Number: 03030684869
- Email: nimranoor358@gmail.com
Study Locations
-
-
Punjab Province
-
Lahore, Punjab Province, Pakistan, 40100
- Nimra Noor
-
Principal Investigator:
- Nimra Noor, MS-CPPT
-
Contact:
- Nimra Noor Nimra Noor, MS-CPPT
- Phone Number: 03030684869
- Email: nimranoor358@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- diagnosed case of copd patients
- Age group:above 10 years
- Clinically stable
- Able to understand or perform breathing exercise
Exclusion Criteria:
- current acute pulmonary infection
- History of pneumothorax or hemoptysis
- Patients who was in stage 4 of functional classification of fatigue,palpation,dyspnea or anginal pain
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Alternate Nostril Breathing
This group receive alternate nostril breathing technique.
This technique includingstress reduction,improved respiratory health and enhanced mental clarity.
Participants will then be instructed to perform this activity 15 to 20 min/day for 4 days/week for 3to 4 weeks.
|
This technique includingstress reduction,improved respiratory health and enhanced mental clarity.
Participants will then be instructed to perform this activity 15 to 20 min/day for 4 days/week for 3to 4 weeks.
|
|
Experimental: bellows breath
This technique drain the excess phlegm from brain.
It improves awareness, focus concentration and productivity.
Participants will then be instructed to performthis activity 10 to 15 min/day for 5 days/week for 3 to 4 weeks.
|
This technique drain the excess phlegm from brain.
It improves awareness, focus concentration and productivity.
Participants will then be instructed to performthis activity 10 to 15 min/day for 5 days/week for 3 to 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Forced Vital Capacity
Time Frame: Baseline and after 4 weeks of intervention
|
Forced Vital Capacity (FVC) will be measured in liters (L) using spirometry.
FVC represents the maximum volume of air that can be forcefully exhaled after a maximal inspiration.
|
Baseline and after 4 weeks of intervention
|
|
Forced Expiratory Volume in One Second
Time Frame: Baseline and after 4 weeks of intervention
|
Forced Expiratory Volume in One Second (FEV₁) will be measured in liters (L) using spirometry.
FEV₁ represents the volume of air exhaled during the first second of a forced expiratory maneuver.
|
Baseline and after 4 weeks of intervention
|
|
FEV₁/FVC ratio
Time Frame: Baseline and after 4 weeks of intervention
|
The FEV₁/FVC ratio will be expressed as a percentage (%) and calculated from spirometric measurements to assess the degree of airflow limitation
|
Baseline and after 4 weeks of intervention
|
|
Health-Related Quality of Life
Time Frame: Baseline and after 4 weeks of intervention
|
The HRQOL (Health-Related Quality of Life) questionnaire is a tool usedtoassess an individual's overall well-being, focusing on how their health impacts their daily life.
It's a 14-item questionnaire developed by the Centers for DiseaseControl and Prevention (CDC) that explores physical, mental, and social healthdomains
|
Baseline and after 4 weeks of intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Arjumand Bano, MS, Riphah International University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2026
Primary Completion (Estimated)
August 1, 2026
Study Completion (Estimated)
August 1, 2026
Study Registration Dates
First Submitted
June 8, 2026
First Submitted That Met QC Criteria
July 17, 2026
First Posted (Actual)
July 22, 2026
Study Record Updates
Last Update Posted (Actual)
July 22, 2026
Last Update Submitted That Met QC Criteria
July 17, 2026
Last Verified
July 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REC/RCR & AHS/25/0310
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COPD (Chronic Obstructive Pulmonary Disease)
-
Ryme Medical, Inc.Not yet recruitingCOPD | Lung Disease, Chronic Obstructive | COPD Patients | COPD Acute Exacerbation | COPD (Chronic Obstructive Pulmonary Disease) | Lung Disease Airways | COPD Exacerbations
-
University College, LondonUniversity of Cambridge; National Institute for Health Research, United Kingdom and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Virginia Commonwealth UniversityFisher and Paykel HealthcareCompletedChronic Obstructive Pulmonary Disease(COPD)United States
-
Reham Mohammed ElmorshedyCompletedChronic Obstructive Pulmonary Disease(COPD)Egypt
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Morair Medtech, LLCRecruitingEmphysema | COPD | Emphysema or COPD | COPD (Chronic Obstructive Pulmonary Disease) | Emphysema, PulmonaryAustria, Germany, Netherlands
-
Medtronic BRCUnknownCOPD | COPD Exacerbation
-
Beaumont HospitalAerogenCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | Copd Exacerbation AcuteIreland
-
Chiesi Farmaceutici S.p.A.CompletedModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
-
Barron Associates, Inc.National Heart, Lung, and Blood Institute (NHLBI); University of VirginiaNot yet recruitingCOPD | COPD - Chronic Obstructive Pulmonary DiseaseUnited States
Clinical Trials on alternate nostril breathing
-
University of MinnesotaRecruitingNausea | Pregnancy EmesisUnited States
-
Foundation University IslamabadRecruiting
-
Children's Mercy Hospital Kansas CityCompletedPregnancy Related | Blood Pressure | Hypertension in PregnancyUnited States
-
Temple UniversityCompletedOcular Hypertension
-
Sialkott College of Physical TherapyCompleted
-
Riphah International UniversityCompleted
-
Riphah International UniversityRecruiting
-
Chang Bing Show Chwan Memorial HospitalUnknown
-
Riphah International UniversityCompleted
-
Foundation University IslamabadRecruiting